Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel
Executive Summary
Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.
You may also be interested in...
Novo Nordisk Gets Approval For Hemophilia B Treatment Sans Postmarketing Requirements
Rebinyn's approval without postmarketing requirements comes as a surprise, given the advisory committee's concerns that the proposed plans weren't robust enough, as well as concerns from FDA about the treatment's safety.
Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel
FDA advisory committee members support approval of investigational hemophilia B treatment nonacog beta pegol but say Novo Nordisk needs more systematic approach to monitoring for neurological and developmental adverse events.
CHMP’s March Recommendations Include Dinutuximab, Nonacog Beta Pegol And Trumenba
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) meets monthly to review applications for centralized EU marketing authorization. Here’s a summary of their March 2017 recommendations.